Clinical characteristics and outcome of patients with Clostridium difficile infection diagnosed by PCR versus a three-step algorithm  by Beaulieu, C. et al.
Clinical characteristics and outcome of patients with Clostridium difﬁcile
infection diagnosed by PCR versus a three-step algorithm
C. Beaulieu1,2, L.-L. Dionne2, A.-S. Julien3 and Y. Longtin1,2,4,5
1) Laval University Faculty of Medicine, 2) Infectious Diseases Research Centre, Centre Hospitalier Universitaire de Quebec, 3) Laval University Faculty of Science
and Engineering 4) Institute of Cardiology and Pneumology, Laval University, Quebec City, and 5) Jewish General Hospital, Montreal, QC, Canada
Abstract
Clinical features of Clostridium difﬁcile infections (CDI) detected by PCR, but not by conventional methods, are poorly understood. We
compared the clinical features of CDI cases detected by PCR only and cases detected by both PCR and a three-step algorithm. We
performed a retrospective cohort study of patients fulﬁlling a standardized deﬁnition over a 13-month period. Stool specimens were tested
in parallel by PCR and an algorithm based on enzyme immunoassay and cytotoxicity assay (EIA/CCA). Clinical features of CDI cases
detected by PCR only and cases detected by PCR and EIA/CCA were compared by univariate logistic regression. In all, 97 patients
(31 PCR+ and 66 PCR+EIA/CCA+) met the inclusion criteria. Compared with cases detected by both PCR and EIA/CCA, CDI cases
detected by PCR only were younger (65.4 versus 76.3 years; p 0.001), had a lower absolute neutrophil count (mean, 9.4 9 109/L
versus 12.5 9 109/L; p 0.04), were less likely to receive oral vancomycin (2/31 versus 25/66; p 0.005) or combination therapy (0/31 versus
16/66; p 0.04), and had fewer complications (6/31 versus 29/66; p 0.02), despite presenting a higher number of bowel movements on the
day of diagnosis (median, 6.0 versus 3.0; p 0.02). They had also a lower C. difﬁcile faecal bacterial load (mean, 5.04 versus 6.89 log10 CFU/g;
p <0.001). The CDI cases detected by PCR only and cases detected by both PCR and EIA/CCA have different clinical features, but whether
these two populations can be managed differently remains to be determined.
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Introduction
Clostridium difﬁcile infection (CDI) is the leading cause of
healthcare-associated infectious diarrhoea [1–4]. It is diag-
nosed mainly by detecting toxigenic C. difﬁcile in the stools of
patients presenting compatible symptoms [2]. This can be
achieved through different assays that differ in terms of
sensitivity, speciﬁcity, cost and turnaround time [1]. Toxi-
genic culture (TC), which involves the selective culture of
C. difﬁcile and the evaluation of its capacity to produce toxin
B (ToxB), remains the reference standard, but it is rarely
performed outside research settings [2]. Cell cytotoxicity
neutralization assay (CCA) detects the presence of ToxB in
stool through its action on cell culture in vitro and is
considered the ‘clinical’ reference standard [2,5]. Despite
high sensitivity, CCA use is decreasing because of its long
turnaround time [4–6]. By contrast, enzyme immunoassays
(EIA) for toxins A and B (ToxA/B) are widely used despite
their lower sensitivity due to their rapid turnaround time and
ease of use [2,5,7]. Another EIA-based method detecting
glutamate dehydrogenase can serve as a screening tool in
combination with more speciﬁc tests [6,8]. Recently,
real-time PCR assays targeting the ToxB gene tcdB have
been commercialized and appear to be very sensitive and
rapid [9–11].
The clinical implications of using a more sensitive assay
such as PCR to diagnose CDI have not been fully elucidated.
Studies that aimed to compare the clinical features of cases
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detected by PCR only and cases detected by both PCR and
by traditional diagnostic methods have yielded conﬂicting
results [12–15]. If the additional cases detected by PCR, but
not by less sensitive methods, are clinically similar to cases
detected by all these methods, their detection would be
clinically relevant because it can impact on patient outcome.
However, if the additional cases detected by PCR are
clinically less severe and have a more favourable outcome,
the importance of detecting these cases may be more
questionable.
Hence, we performed a study to compare the clinical
features of patients with CDI who tested positive for C. difﬁcile
by PCR only with those who were diagnosed by both PCR and
a toxin-based algorithm. We hypothesized that cases detected
by PCR only are clinically less severe than cases detected by
both PCR and a toxin-based algorithm. Moreover, to shed
light on the factors underlying a potential discrepancy in
clinical features, we quantiﬁed C. difﬁcile load in stool samples
by quantitative culture and analysis of PCR cycle thresholds
(CT).
Methods
Study design and setting
Laval University Institute of Cardiology and Pneumology
(IUCPQ) is a 350-bed primary and tertiary academic
healthcare facility admitting 13 000 patients annually. The
institution implemented a commercial PCR for C. difﬁcile in
August 2010 [16]. To document the performance of this
new test, all stool samples sent to the laboratory for
suspected CDI between August 2010 and September 2011
were prospectively tested in parallel by both PCR and an
algorithm combining an EIA and CCA (hereafter referred to
as EIA/CCA) [16]. We performed a retrospective review of
the medical records of all adult patients with CDI who were
hospitalized during this period. Patients were identiﬁed
through the infection control electronic databases. Cases
that met the following criteria were eligible for inclusion: (i)
hospitalized patient diagnosed with an episode of CDI; (ii)
for whom the presence of toxigenic C. difﬁcile was estab-
lished with a positive PCR test and conﬁrmed by TC; and
(iii) for whom the presence of C. difﬁcile was also assessed
by EIA/CCA. Recurrent cases (deﬁned as a second CDI
episode occurring within 8 weeks of a previous episode)
were excluded. Patients were divided into two groups: the
reference group included all patients who tested positive by
both PCR and by EIA/CCA, whereas the experimental group
included all patients who tested positive by PCR, but not by
EIA/CCA.
Clinical data and deﬁnitions
The standardized Quebec CDI surveillance deﬁnition was
used to deﬁne CDI; this requires a clinical history of
diarrhoea (i.e. at least three unformed stools in <24 h and
symptoms lasting ≥24 h) without other known aetiology
combined with a positive result for the presence of toxigenic
C. difﬁcile in the stool [17]. Data were extracted from the
patient’s medical records using a structured report form.
Variables analysed included demographic variables, comor-
bidities, clinical features, laboratory characteristics, choice
and duration of therapy and clinical outcomes. Reviewers,
physicians and the infection control team were blinded to the
result of EIA/CCA, and patient management was based on
the result of PCR.
Microbiological methods
All unformed stool samples submitted for C. difﬁcile testing
were analysed in parallel using two different diagnostic
approaches: (i) a one-step assay based on the detection of
tcdB gene by PCR (BD GeneOhm CDiff, Franklin Lakes, NJ,
USA), and (ii) a three-step algorithm detecting glutamate
dehydrogenase (Diff Chek-60, Techlab, Blacksburg, VA,
USA) and ToxA/B by EIA/CCA (ToxA/B Quik-Check,
Techlab) or CCA (Bartels Immunodiagnostic Supply, Belle-
vue, WA, USA) [6,16]. The complete algorithm has been
described previously and is summarized in Fig. 1 [16].
Results of PCR were transmitted to the wards within 24 h.
All samples positive by PCR were divided into aliquots and
stored at 80°C for subsequent quantiﬁcation and TC as
previously described [18]. Written authorization was
obtained from the manufacturer to extract cycle threshold
(CT) values of every PCR-positive sample from the
recorded data ﬁles.
Statistical analysis
Descriptive characteristics are expressed as the mean 
standard deviation (SD), as median and interquartile range
(IQR) or as a percentage of the group from which they are
derived (categorical variables). To assess the differences in
clinical features between CDI cases detected by PCR only and
cases detected by both PCR and EIA/CCA, univariate logistic
regression was used. As our goal was to compare the clinical
characteristics rather than identify independent risk factors, a
multivariate analysis was not performed [19]. Firth bias-
correction was used to correct separation problems. Results
are reported as OR and accompanying 95% CI. A p-value <0.05
was considered to be signiﬁcant. All analyses were performed
with SAS version 9.2.
This study was approved by the institutional review board
of Laval University Institute of Cardiology and Pneumology.
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Results
Study population
During the study period, 1470 stool samples were tested in
parallel by PCR and EIA/CCA; 245 specimens were positive by
PCR (Fig. 2). Of these, 76 (31%) were positive by PCR only
and 169 (69%) were positive by both PCR and EIA/CCA. One
hundred and twenty specimens (29 positive by PCR only and
91 positive by both PCR and EIA/CCA) were excluded for the
following reasons: 66 were from non-hospitalized patients, 39
were recurrences, six were duplicates and nine charts were
unavailable. Hence, 125 charts were reviewed. Twenty-eight
additional cases were excluded because they did not fulﬁl the
inclusion criteria (six had a clear alternative cause for the
symptoms, and 22 were not conﬁrmed by TC). Ninety-seven
patients were included in the ﬁnal analysis (31 who tested
positive by PCR only, and 66 who tested positive by both PCR
and EIA/CCA).
Characteristics of patients with CDI
Demographics and clinical characteristics of the study popu-
lation are shown in Table 1. The mean age of patients was
72.8 years, and 53.6% were female. The average length of
hospital stay was 23.8 days. Nine patients (9.5%) had a
previous history of CDI. Most CDI cases (80.4%) were
healthcare-associated. Most patients (89.7%) had received
antibiotics in the previous 8 weeks, and 35 patients (36%)
were still receiving antibiotic therapy at the time of diagnosis.
The mean absolute neutrophil count was 11.4 9 109/L and the
median number of bowel movements on the day of diagnosis
was 4.0 (IQR 2.6). The median duration of antibiotic therapy
for CDI was 14(IQR 10-21) days. Most patients (86.6%) were
treated with metronidazole, and approximately one-quarter
(27.8%) received oral vancomycin. Sixteen patients (16.5%)
received a combination of oral vancomycin and intravenous
metronidazole as initial therapy. Twelve patients (14%) died
within 30 days of diagnosis, four patients (4.1%) were admitted
to the intensive care unit (ICU) for a CDI-related issue, one
patient (1%) had a colectomy, and 22 (29.3%) presented a
recurrence of CDI within 8 weeks. Overall, at least one
complication (deﬁned as either admission to the ICU, colec-
tomy, recurrence, or 30-day mortality) occurred in 35 patients
(36.1%). At 1-year follow up (or at hospital discharge if no
further information was available), 19 patients (19.6%) had died
from any cause.
Univariate analysis
By univariate analysis, patients with CDI detected by PCR, but
not by EIA/CCA, were younger (average age 65.4 versus 76.3;
p 0.001) with a lower absolute neutrophil count (average,
9.4 9 109/L versus 12.5 9 109/L; p 0.04), and were less likely
to receive oral vancomycin (6.5% versus 37.9%; p 0.005) or
combination therapy (0% versus 24.2%; p 0.04) than cases
detected by both PCR and EIA/CCA. They were also less likely
to present at least one complication such as ICU admission,
colectomy, recurrence, or 30-day mortality (19.4% versus
43.9%; p 0.02) and to have died at 1-year follow up (6.5%
versus 25.8%; p 0.04). Surprisingly, these patients also pre-
sented more bowel movements on the day of diagnosis than
FIG. 1. Flow chart of laboratory diagnosis
ofClostridiumdifﬁcile in stool samplesbyPCR
and by the three-step algorithm. Abbrevia-
tions: tcdB, Toxin B gene; GDH, glutamate
dehydrogenase Blacksburg, VA); EIA,
enzyme immunoﬂuorescent assay; ToxAB,
C. difﬁcile toxins A or B; CCA, cell culture
cytotoxicity assay.
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cases detected by both PCR and EIA/CCA (median, 6.0 versus
3.0 bowel movements; p 0.02). Length of stay (average, 17.3
versus 26.8; p 0.08) and duration of therapy (median, 10
versus 14 days; p 0.10) tended to be shorter in cases detected
only by PCR, although the difference did not reach statistical
signiﬁcance. There was no signiﬁcant difference between the
two groups in terms of comorbidities, occurrence of fever,
total white blood cell count, and duration of therapy (p >0.05).
Finally, cases detected by PCR, but not by EIA/CCA, had a
lower C. difﬁcile faecal load (average, 5.04 versus 6.89
log10 CFU/g; p <0.001) and had a higher CT (average, 33.9
versus 29.2 cycles; p <0.001) than cases detected by both PCR
and EIA/CCA.
Discussion
Ourstudy shows thatCDIcasesdetectedbyPCR,butnotbyEIA/
CCA, are clinically less severe than cases detected by both PCR
and EIA/CCA as they tend to be younger, have a lower absolute
neutrophil count at diagnosis, and have a more favourable
outcome, despite being signiﬁcantly less likely to receive
vancomycin therapy or a combination therapy. The clinical
signiﬁcance of detecting C. difﬁcile using a highly sensitive assay
such as nucleic acid ampliﬁcation test without the concomitant
detection of toxin by EIA or CCA is highly debated, and previous
studies have yielded conﬂicting results [12,15,20–22].
An early study comparing 42 CDI cases positive by PCR, but
not ToxA/B by EIA, and 90 CDI cases positive by both
methods did not ﬁnd any signiﬁcant differences between these
two groups and concluded that EIA for toxin should not be
relied upon as a sole test for the diagnosis of CDI [15]. A
second study comparing retrospectively 56 CDI cases
detected by PCR, but not by CCA, and 72 cases detected by
both tests also failed to detect a difference in clinical severity
and outcome in a cancer patient population [12]. Another
retrospective study of 143 CDI cases did not detect any
signiﬁcant difference in disease severity between cases
detected only by a loop-mediated isothermal ampliﬁcation
(LAMP) assay and cases detected by both LAMP and EIA [21].
FIG. 2. Enrolment and Group Assign-
ment. Abbreviations: PCR, detection of
Toxin B gene tcdB by polymerase chain
reaction; EIA/CCA, detection of toxigenic
Clostridium difﬁcile by enzyme immunoa-
ssay and cell culture cytotoxicity assay;
TC, toxigenic culture.
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Although the reasons behind the lack of clinical difference in
the latter study is not clear, it could be a result of the lower
sensitivity of LAMP compared with PCR [23].
By contrast, other studies support the notion that clinical
presentations and outcomes may vary depending on the
sensitivity of the diagnostic test [20,22,24]. A large retrospec-
tive study of patients with CDI compared the clinical
performance of TC and CCA and showed that detecting the
presence of toxigenic C. difﬁcile by TC without concomitant
detection of toxin by CCA is associated with a lower mortality
rate, shorter hospital stay and lower white blood cell count
compared with cases positive by both TC and CCA [20]. The
relationship between toxin production and a higher white
blood cell count is also supported by other studies [22]. By
quantifying C. difﬁcile fecal load using quantitative culture, our
study provides an additional glimpse into one of the potential
mechanisms underlying the difference in clinical presentation.
These results conﬁrm previous research showing that CDI
cases detected by PCR only have a higher CT than cases
detected by both PCR and CCA [12].
TABLE 1. Clinical characteristics and outcome of patients with Clostridium difﬁcile infection detected by PCR only or by both
PCR and EIA/CCA
Explanatory variable
Overall population
(n = 97)
C. difﬁcile detected
by PCR only (n = 31)
C. difﬁcile detected by
PCR and EIA/CCA (n = 66) OR (95% CI) p-value
Demographic characteristics
Age, years (SD) 72.8 (14.1) 65.4 (5.5) 76.3 (12.1) 0.94 (0.91–0.98) 0.001
Female (%) 52 (53.6) 15 (43.4) 37 (56.1) 0.74 (0.31–1.73) 0.48
Average length of stay (days) 23.8 (24.0) 17.3 (20.6) 26.8 (25.1) 0.98 (0.98–1.00) 0.08
Comorbidities and past medical history
Previous history of CDI (%) 9/95 (9.5) 1/30 (3.3) 8/65 (87.7) 0.25 (0.03–2.06) 0.20
Previous colectomy (%) 3 (3.1) 1 (3.2) 2 (3.0) 1.07 (0.09–12.24) 0.96
Previous bariatric surgery (%) 4 (4.1) 2 (6.5) 2 (3.0) 2.21 (0.30–16.44) 0.44
Diabetes mellitus (%) 33 (34.0) 9 (29.0) 24 (36.4) 0.72 (0.28–1.80) 0.48
COPD (%) 30 (30.9) 9 (29.0) 21 (31.8) 0.88 (0.35–2.23) 0.78
Renal insufﬁciency a(%) 8/96 (8.3) 1/30 (3.3) 7 (10.6) 0.29 (0.03–2.48) 0.26
Malignancy (%) 16 (16.5) 7 (22.6) 9 (13.6) 1.85 (0.62–5.54) 0.27
Chemotherapy (%) 5 (5.2) 3 (9.7) 2 (3.0) 3.43 (0.54–21.66) 0.19
Congestive heart failure b(%) 23 (23.7) 4 (12.9) 19 (28.8) 0.37 (0.11–1.19) 0.09
Coronary artery disease (%) 44 (45.4) 10 (32.3) 34 (51.5) 0.45 (0.19–1.057) 0.07
Cirrhosis (%) 2 (2.1) 1 (3.2) 1 (1.5) 2.17 (0.13–35.82) 0.59
Immunosuppressive drug use c (%) 7 (7.4) 3 (10.3) 4 (6.1) 1.79 (0.37–8.56) 0.47
Clinical characteristics of CDI episode
Healthcare-associated CDI (%) 78 (80.4) 24 (77.4) 54 (79.41) 0.963 (0.35–2.67) 0.94
Antibiotics prescribed in last 8 weeks (%) 87 (89.7) 28 (90.3) 59 (89.4) 1.11 (0.27–4.61) 0.89
Active antibiotic prescription (%) 35 (36.0) 12 (38.7) 23 (34.8) 1.18 (0.49–2.85) 0.71
Median number of bowel movements d(IQR) 4.0 (2–6) 6.0 (3–10) 3.0 (2–5) 1.132 (1.02–1.26) 0.02
Fever >38.3°C (%) 27/93 (29.0) 8/30 (26.7) 19/63 (30.16) 0.84 (0.32–2.22) 0.73
Vomiting (%) 8/91 (8.9) 4/25 (16.0) 4 (6.1) 2.95 (0.68–12.86) 0.14
Acute renal failure e(%) 20/91 (22.0) 4/29 (13.8) 16/62 (25.8) 0.46 (0.14–1.53) 0.20
Dehydration f(%) 37/88 (40.0) 12/23 (52.2) 23/65 (35.4) 1.99 (0.76–5.22) 0.16
Shock (%) 6 (6.2) 1 (3.2) 5 (7.6) 0.41 (0.05–3.64) 0.42
Biomarkers
Max WBC count (9109/L) mean (SD) 14.1 (7.8) 12.7 (9) 14.8 (7.1) 0.96 (0.90–1.03) 0.22
Neutrophil count (9109/L) mean, (SD) 11.4 (6.5) 9.4 (4.9) 12.5 (7.0) 0.92 (0.84–0.997) 0.04
Mean C. difﬁcile faecal load, log0 CFU/g (SD) 6.30 (1.45) 5.04 (1.27) 6.89 (1.11) 0.27 (0.16–0.47) <0.001
PCR assay cycle threshold (SD) 30.7 (4.43) 33.9 (4.9) 29.2 (3.3) 1.30 (1.16–1.47) <0.001
Alternative cause for diarrhoea
Laxative use (%) 21/79 (26.7) 7/23 (30.4) 14/56 (25.0) 1.31 (0.45–3.84) 0.62
Enteral feeding (%) 3 (3.1) 2 (6.5) 1/66 (1.5) 4.41 (0.39–50.65) 0.23
Therapy
Metronidazole (%) 84 (86.6) 27 (87.1) 57 (86.4) 1.07 (0.30–3.71) 0.92
Vancomycin (%) 27 (27.8) 2 (6.5) 25 (37.9) 0.11 (0.03–0.52) 0.005
Initial combination therapy (%) 16 (16.5) 0 (0) 16 (24.2) 0.05 (0.00–0.91) 0.04
Median length of treatment, days g (IQR) 14.0 (10–21) 10.0 (10–14) 14.0 (10–21) 0.97 (0.93–1.01) 0.10
Complications and outcome
ICU admission (%) 4 (4.1) 0 (0) 4 (6.1) 0.22 (0.00–5.94) 0.37
Colectomy (%) 1 (1.0) 0 (0) 1 (1.5) n/a n/a
Recurrence h (%) 22/75 (29.3) 5/25 (20.0) 17/50 (34.0) 0.49 (0.16–1.52) 0.21
30-day mortality (%) 12/86 (14.0) 1/26 (3.8) 11/60 (18.3) 0.18 (0.02–1.46) 0.11
At least one complication
(one or more of the above) (%)
35 (36.1) 6 (19.4) 29 (43.9) 0.31 (0.11–0.85) 0.02
1-year mortality (%) 19 (19.6) 2 (6.5) 17 (25.8) 0.20 (0.04–0.92) 0.04
Data are no. of patients with characteristic/no. of patients with information available (%), unless otherwise speciﬁed.
Abbreviations: CDI, C. difﬁcile infection; PCR, detection of Toxin B gene tcdB by polymerase chain reaction; EIA/CCA, detection of glutamate dehydrogenase antigen and ToxA/B
by enzyme immunoassay or cell culture cytotoxicity assay; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; ICU, intensive care unit; WBC, white blood
cell; log10 CFU/g: colony-forming unit per gram of stool (logarithmic scale); n/a, not available.
aDeﬁned as glomerular ﬁltration rate <30 mL/min/1.73 m2
bDeﬁned as an ejection fraction <50%
c>10 mg of prednisone (or equivalent) for at least 2 consecutive weeks.
dOn the day of diagnosis.
eDeﬁned as 1.5-fold increase in the baseline serum creatinine or a ≥25% decrease in glomerular ﬁltration rate.
fDeﬁned as administration of intravenous ﬂuids in bolus or at the rate exceeding basal needs.
gn = 91 (six missing).
hDeﬁned as recurrence of symptoms and a test positive for the presence of C. difﬁcile in stools within 8 weeks of completion of treatment for a previous C. difﬁcile infection.
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The higher number of bowel movements in cases detected
by PCR only was unexpected. When assessing the signiﬁcance
of this ﬁnding, it is worth noting that the number of bowel
movements is a poor indicator of disease severity [2,25,26]. As
cases detected by PCR only were younger and had a lower
neutrophil count, these patients had a lower pre-test proba-
bility of having CDI. We hypothesize that physicians were less
prompt to test for C. difﬁcile in this population and may have
restricted testing to patients with more ﬂorid symptomatology
(i.e. a high number of bowel movements). Alternatively, this
ﬁnding may be due to the inherent difﬁculty of collecting these
data accurately in an elderly population. Clearly, additional
studies will be required to conﬁrm this ﬁnding.
Whether cases detected by PCR only, but not by EIA/CCA,
genuinely represent less severe cases or cases diagnosed earlier
in the course of the disease (and hence more promptly treated)
remains to be determined. Some of these cases could represent
patients who are colonized by toxigenic C. difﬁcile who coinci-
dentally present diarrhoea for another unrelated and unrecog-
nized reason. Alternatively, it could be linked also with a higher
systemic anti-toxin antibody response to C. difﬁcile infection in
younger patients [27]. The use of markers of colonic inﬂamma-
tion, such as lactoferrin, could help to distinguish these different
hypotheses [28]. The presence of toxin may have prognostic
implications. Preliminary data suggest that gastrointestinal
symptoms of patients with a positive nucleic acid ampliﬁcation
test for C. difﬁcile, but a negative toxin test, can improve without
any speciﬁc CDI treatment [24].
Limitations of the study
Our study has some limitations. It was performed in a single
centre with a high (>50%) prevalence of CDI caused by NAP1
strain [18] and used a single commercial PCR. Caution should be
applied in extrapolating these data to other settings and
diagnostic assays [29]. As in any retrospective study, access to
data was sometimes limited. For example, the proportion of
patients who received an empirical therapy could not be
determined in our population. Also, recurrent cases and
PCR-positive samples that were not conﬁrmed by TC were
excluded from the study. Hence, our study cannot determine
whether these populations are clinically different from the ones
included in the present study. Even though it was comparable to
other published studies [12,15,22,24], sample size was relatively
modest due to strict case deﬁnition and inclusion criteria.
Conclusions
Our ﬁndings suggest that CDI cases detected by PCR alone
tend to have a different clinical presentation, a more favour-
able outcome, and a lower burden of C. difﬁcile in their stools
than cases detected by both PCR and a traditional toxin-based
method. Prospective studies are needed to substantiate these
ﬁndings and to better understand the optimal management of
this population.
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